文献速递多重用药衰弱、肌少症与跌倒老年慢病共病管理

多重用药管理:应对重大公共卫生危机的新策略

Polypharmacy stewardship: a novel approach to tackle a major public health crisis.
PubMed 文献 · Lancet Healthy Longev · 2023-04-05

本文回应WHO 2017年「无伤害用药」全球患者安全挑战,提出广谱多重用药管理(polypharmacy stewardship)新概念。该策略针对多病共存、多重用药和碎片化医疗导致的用药相关伤害,统筹潜在不适当用药、潜在处方遗漏、药物相互作用及处方级联,使治疗方案与患者病情、预后和偏好相匹配。其安全性和有效性尚需设计良好的临床试验验证。

要点

  • 多病共存、多重用药和碎片化医疗是用药相关伤害的关键驱动因素,尤其影响75岁以上衰弱老年人。
  • 既往药物管理干预聚焦窄谱潜在不良用药实践,结果不一。
  • 广谱多重用药管理统筹潜在不适当用药、处方遗漏、药物相互作用和处方级联。

核心结论

  • 广谱多重用药管理可能减少多病共存且多重用药老年人的用药相关伤害,但其安全性和有效性尚需设计良好的临床试验验证。

研究设计与样本

  • 本文为概念性文章,回应WHO于2017年3月启动的「无伤害用药」全球患者安全挑战,提出广谱多重用药管理新概念,未报告系统检索方法或样本量。

主要发现

  • 多病共存、多重用药和碎片化医疗是用药相关伤害的关键驱动因素,可导致功能不良结局、高住院率和超额发病率与死亡率,尤其在75岁以上衰弱患者中。
  • 部分研究已考察老年队列中的药物管理干预效果,但聚焦窄谱潜在不良用药实践,结果不一。

关键数值与推荐

  • 广谱多重用药管理为协调性干预,涵盖潜在不适当用药、潜在处方遗漏、药物-药物及药物-疾病相互作用和处方级联。
  • 该策略使治疗方案与个体患者的病情、预后和偏好相匹配。

临床怎么用

  • 原文提出广谱多重用药管理可作为改善多病共存患者多重用药管理的协调性干预思路,其安全性和有效性尚待临床试验验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With growing global concern regarding medication-related harm, WHO launched a global patient safety challenge, Medication Without Harm, in March, 2017. Multimorbidity, polypharmacy, and fragmented health care (ie, patients attending appointments with multiple physicians in various health-care settings) are key drivers of medication-related harm, which can result in negative functional outcomes, high rates of hospitalisation, and excess morbidity and mortality, particularly in patients with frailty older than 75 years. Some studies have examined the effect of medication stewardship interventions in older patient cohorts, but focused on a narrow spectrum of potentially adverse medication practices, with mixed results. In response to the WHO challenge, we propose the novel concept of broad-spectrum polypharmacy stewardship, a coordinated intervention designed to improve the management of multimorbidities, taking into account potentially inappropriate medications, potential prescribing omissions, drug-drug and drug-disease interactions, and prescribing cascades, aligning treatment regimens with the condition, prognosis, and preferences of the individual patient. Although the safety and efficacy of polypharmacy stewardship need to be tested with well designed clinical trials, we propose that this approach could minimise medication-related harm in older people with multimorbidities exposed to polypharmacy.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Daunt R, Curtin D, O'Mahony D, et al. Polypharmacy stewardship: a novel approach to tackle a major public health crisis. Lancet Healthy Longev. 2023. PMID: 37030320. doi:10.1016/S2666-7568(23)00036-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。